blank
blank

ERDERA Clinical Trial Call 2026 – Call Text

1:1
Call text draft setting out rules, eligibility and staged application process for the ERDERA Clinical Trial Call 2026. [ERDERA_Cli...t_20260603 | PDF]

Call text draft for the ERDERA Clinical Trial Call 2026, describing governance, scope (in scope/out of scope), funding mechanism, eligibility criteria, application stages (including Stage 0 Expression of Interest and Stage 1 Short Proposal), evaluation, and annexed definitions and indicative timeline. It includes submission deadlines for Expressions of Interest (10 September 2026) and Short Proposals (29 October 2026) and provides a contact email for the Scientific Secretariat.

Acces this publication
blank

publication

ERDERA CTC 2026

Year of publication

2026

Source

European Rare Diseases Research Alliance (ERDERA)

Author

You might also be interested in

ECRD 2026

ECRD 2026 in Prague strengthens the push for a coordinated EU Action Plan on rare diseases

On 3–4 June, EURORDIS–Rare Diseases Europe and Orphanet convened the rare disease community at ECRD 2026 in Prague around a shared call for coordinated European action, including the forthcoming European Blueprint for Rare Diseases.
Publication

Understanding ERDERA: Europe’s alliance for rare disease research

30 million people in Europe live with a rare disease. Yet most still lack a diagnosis or treatment. So what is ERDERA doing about it?
European Biotech Act 062026

ERDERA Policy Brief: European Biotech Act

The European Rare Diseases Research Alliance (ERDERA), together with the European Reference Networks (ERNs), provides the missing operational layer required to implement the European Biotech Act across the full innovation pathway —from discovery to patient access.
ERDERA JTC 2026 (1)

ERDERA Clinical Trial Call 2026 – Information Webinar

July 6 @ 3:00 pm - 5:00 pm

ERDERA's

search form